Sensible

Sensible Biotechnologies is a biopharmaceutical company developing a novel platform for the production of high-quality mRNA. Unlike traditional in vitro transcription (IVT) methods, Sensible utilizes a cell-based approach to manufacture mRNA, which aims to improve the yield, length, and stability of the molecules while reducing impurities like double-stranded RNA. The company's technology is designed to enable the development of complex mRNA therapeutics and vaccines that were previously difficult to produce using conventional techniques. By leveraging synthetic biology and engineered cellular systems, Sensible seeks to scale mRNA manufacturing to meet global demand for diverse clinical applications. The platform is particularly focused on overcoming the limitations of current mRNA synthesis to support the next generation of genetic medicines.